

Supplement Materials

Figure Legends

Fig. S1. Sensitivity analysis for plasma D-dimer level and lung cancer associated mortality.

Fig. S2. Begg's test plot (**A**) and Egger linear regression test (**B**) with 95% CI for the relationship between plasma D-dimer level and lung cancer associated mortality.

Fig. S3A. Risk of bias graph: review author's judgements about each risk of bias item percentages across all included studies.

Fig. S3B. Risk of bias summary: review author's judgements about each risk of bias item percentages across all included studies.

Table S1. Quality of Evidence evaluated by GRADE system

Author	Year	Design	Downgrade quality of evidence				Publication Bias	Upgrade quality of evidence		Quality of Evidence	
			Risk of Bias	Inconsistency	Indirectness	Imprecision		Large effect	No FWE		
Fan, S	2019	RS	serious(-1)	serious(-1)	no	serious(-1)	serious(-1)	no	no	Low ①②③	
Minglei, Y	2019	RCT	no	no	serious(-1)	no	undetected	large (+1)	no	High ④⑤⑥	
Hou, C	2019	PCS	no	serious(-1)	no	no	undetected	no	no	Moderate ③④⑤	
Huangliang, L	2019	RS	serious(-1)	no	serious(-1)	no	serious(-1)	no	serious(-1)	Low ①②③	
Edya I, W	2018	PCS	no	serious(-1)	no	no	undetected	no	no	Moderate ③④⑤	
Cuicui, Z	2018	RS	serious(-1)	no	serious(-1)	no	serious(-1)	no	serious(-1)	Low ①②③	
Wenwen, S	2017	PCS	no	serious(-1)	no	no	undetected	no	no	Moderate ③④⑤	
Kun, S	2017	PCS	no	no	no	serious(-1)	no	undetected	no	Very low ①②③④⑤	
L-R, Zhu	2016	PCS	no	no	no	no	undetected	large (+1)	no	High ④⑤⑥	
Magdalena, Z	2016	PCS	serious(-1)	no	no	no	undetected	no	no	Moderate ③④⑤	
Koichi, F	2015	PCS	no	no	no	serious(-1)	no	undetected	no	Moderate ③④⑤	
Yuezhen, W	2015	RS	serious(-1)	serious(-1)	no	serious(-1)	undetected	no	no	Low ①②③	
Tuba, I	2015	PCS	no	serious(-1)	no	no	undetected	no	no	Moderate ③④⑤	
L-P, Ge	2014	PCS	no	no	no	serious(-1)	no	undetected	no	Moderate ③④⑤	
Heguo, J	2014	PCS	no	serious(-1)	no	no	undetected	no	no	High ④⑤⑥	
P-P, Zhang	2013	PCS	no	no	no	no	undetected	no	no	Moderate ③④⑤	
Cihai, A	2012	PCS	no	no	no	serious(-1)	no	undetected	large (+1)	no	Moderate ③④⑤
Katsuhiro, M	2011	PCS	no	serious(-1)	no	no	undetected	no	no	Moderate ③④⑤	
G. Altay	2007	PCS	serious(-1)	no	no	no	undetected	no	no	Moderate ③④⑤	

Table S2. Overview of multivariable relationship of D-dimer with lung cancer

Author	Year	HR [95% CI]	Adjusted Covariate
Fan, S	2019	2.73 [1.32-5.63]	KPS score, N-Stage, TNM-Stage, Treatment, NSE
Minglei, Y	2019	1.28 [1.1-1.5]	Age, Visceral metastases, Number of metastases in the vertebral body, Frankel score, EGFR mutation
Hou, C	2019	1.61 [0.66-3.93]	Gender, anatomic location, LVI, VPI, TNM stage, and tumor size.
Huangliang, L	2019	1.27 [1-1.61]	Smoking, Lesion type, Resection type T stage, Lymph node metastasis Fibrinogen level, NLR, PLR, LMR
Edyta I. W	2018	1.81 [1.09-2.98]	None
Cuicui, Z	2018	0.92 [0.86-1.23]	None
Wenwen, S	2017	3.33 [2.03-5.45]	None
Kaoru, S	2017	2.24 [1.05-4.69]	Age, Serum CEA, SUVmax of primary tumor, Pleural invasion, Pathological stage Stage
L-R, Zhu	2016	3.21 [0.96-11.34]	Age, gender, ECOG-PS, Tumor Stage, Response to chemotherapy, Fibrinogen, NSE, CEA, LDH
Magdalena, Z	2016	3.03 [1.22-7.69]	Age, Rash, Dominant histological diagnosis, Deletion in exon 19, Substitution in exon 21, Clinical stage, Karnofsky performance, Gender, Cardiovascular diseases, Prophylaxis with LWMH, Smoking, Previous thoracic surgery, Previous radiotherapy, Previous chemotherapy, Pre-treatment level of D-dimer
Koichi, F	2015	4.25 [1.65-10.91]	Age, Sex, Smoking history, p-stage, Histology, Surgical procedure, CEA
Yuezhen, W	2015	1.24 [1.12-1.38]	Sex, Age, smoking history, histology, TNM stage, PS
Tuba, I	2015	3.55 [1.63-7.77]	Hemoglobin pretreatment, APTT, LDH
L-P, Ge	2014	0.91 [0.35-1.75]	Tumor stage, Number of metastatic sites, Treatment response, CEA, Cyfra 21-1
Heguo, J	2014	3.28 [1.12-8.92]	Lymph node status, Pathologic stage, Plasma fibrinogen, Serum CEA, Serum Cyfra 21-1
P-P, Zhang	2013	1.54 [1.11-2.78]	Age, Sex, Histology, Tumor size, TNM stage, VTE, Surgery,
Cihan, A	2012	1.30 [1.20-1.40]	Gender, Age, Different tumor groups, Venous thromboembolism
Katsuhiro, M	2011	1.57 [1.17-2.19]	None
G. Altay	2007	4.32 [2.18-8.55]	Tumour stage, Karnofsky performance, status

Abbreviation: KPS, Karnofsky Performance Status; NSE, neuron Specific enolase; LVI, lymphovascular invasion; VPI, visceral pleural invasion; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; LMR, lymphocyte-monocyte ratio; HR, hazard ratio; CEA, carcinoembryonic antigen; LDH, lactate dehydrogenase; ECOG, Eastern Cooperative Oncology Group; PS, performance status; LWMH, low molecular weight heparin; APTT, activated partial thromboplastin time.

Figure S1




Figure S2A




Figure S2B




Figure S3A




Figure S3B

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Cihan, A 2012	+	-	+	+	+	+	+
Cuicui, Z 2018	-	-		+		-	
Edyta I. W 2018	+	-	+	+	-	+	+
Fan, S 2019	-	-	-	+		-	+
G. Altaiay 2007	+		+	+	+	+	+
Heguo, J 2014	-	-		+	+	+	+
Hou, C 2019	-	+	+	-	+	+	+
Huangliang, L 2019	-	+		+	-	+	-
Kaoru, S 2017		+	+	+	+	+	+
Katsuhiro, M 2011	+	-		+	+	+	+
Koichi, F 2015	+	+	-	+	+	+	+
L-P, Ge 2014	+	-	-	+	+	+	+
L-R, Zhu 2016	-	+	+	-	+	+	+
Magdalena, Z 2016	+	+	+		+	+	+
Minglei, Y 2019	+	+	+	+	+	+	+
P-P, Zhang 2013	-	+	-	+	+	+	+
Tuba, I 2015	-	+	+	-	+	+	+
Wenwen, S 2017	-	+	-	+	+	-	+
Yuezhen, W 2015	-	-	+	+	-	+	+